CVS Health Corp. Revenue & Financials

CVS Health's financial profile in fiscal year 2024 reflects the tension between extraordinary scale and profitability under pressure. Total revenues reached approximately $372 billion, a figure that places CVS among the top five largest companies in the United States by this measure — yet much of this revenue represents pharmaceutical product costs flowing through the PBM and insurance segments rather than margin-generating operating income. The company's adjusted operating income, a measure that strips out depreciation, amortization of acquired intangibles, and restructuring charges, provides a cleaner picture of economic performance, and that figure declined meaningfully in 2024 relative to prior years, driven primarily by Aetna's elevated medical cost ratios in its Medicare Advantage business. The Health Care Benefits segment — Aetna — reported a medical loss ratio that breached 90 percent in multiple quarters of 2024, a level that signals minimal or negative underwriting margin. This drove CVS to reduce its full-year earnings guidance multiple times during 2024 and ultimately contributed to net losses that surprised even cautious analysts. The company's net income for fiscal year 2024 was approximately $4.6 billion on a GAAP basis, though this figure includes significant charges. Long-term debt stood at approximately $73 billion, a legacy of the Aetna and other acquisitions, which creates meaningful interest expense that further pressures earnings. The Health Services segment (Caremark) remains the most profitable segment on an adjusted basis, contributing the majority of CVS's adjusted operating income. The Pharmacy & Consumer Wellness segment generates substantial revenue but thin margins reflective of retail pharmacy economics. CVS generated approximately $9 billion in operating cash flow in 2024, which it has used to service debt, fund capital expenditures including Oak Street center openings, and maintain its dividend — currently approximately $2.66 per share annually.